{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,4]],"date-time":"2026-10-04T09:22:04Z","timestamp":1791105724959,"version":"4.1.0"},"reference-count":78,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2013,8,1]],"date-time":"2013-08-01T00:00:00Z","timestamp":1375315200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neuropharmacology"],"published-print":{"date-parts":[[2013,8]]},"DOI":"10.1016\/j.neuropharm.2013.03.038","type":"journal-article","created":{"date-parts":[[2013,4,17]],"date-time":"2013-04-17T03:40:24Z","timestamp":1366170024000},"page":"191-203","source":"Crossref","is-referenced-by-count":42,"special_numbering":"C","title":["\u03b14\u03b22 nicotinic receptors play a role in the nAChR-mediated decline in l-dopa-induced dyskinesias in parkinsonian rats"],"prefix":"10.1016","volume":"71","author":[{"given":"Maryka","family":"Quik","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanuja","family":"Bordia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jon-Paul","family":"Strachan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jenny","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"J. Michael","family":"McIntosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sharon","family":"Letchworth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kristen","family":"Jordan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.neuropharm.2013.03.038_bib1","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1007\/s11910-003-0005-1","article-title":"Parkinson's disease: is the initial treatment established?","volume":"3","author":"Ahlskog","year":"2003","journal-title":"Curr. Neurol. Neurosci. Rep."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib2","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1152\/physrev.00015.2008","article-title":"Mammalian nicotinic acetylcholine receptors: from structure to function","volume":"89","author":"Albuquerque","year":"2009","journal-title":"Physiol. Rev."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib3","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1016\/0165-0270(90)90139-7","article-title":"The use of 3H standards in 125I autoradiography","volume":"32","author":"Artymyshyn","year":"1990","journal-title":"J.\u00a0Neurosci. Methods"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib4","doi-asserted-by":"crossref","first-page":"828","DOI":"10.1016\/j.bcp.2011.04.019","article-title":"An autoradiographic survey of mouse brain nicotinic acetylcholine receptors defined by null mutants","volume":"82","author":"Baddick","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib5","doi-asserted-by":"crossref","first-page":"886","DOI":"10.1016\/S0022-3565(24)37321-5","article-title":"The heterocyclic substituted pyridine derivative (+\/\u2212)-2-(-3-pyridinyl)-1-azabicyclo[2.2.2]octane (RJR-2429): a selective ligand at nicotinic acetylcholine receptors","volume":"284","author":"Bencherif","year":"1998","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib6","doi-asserted-by":"crossref","first-page":"577","DOI":"10.1038\/35086062","article-title":"Pathophysiology of levodopa-induced dyskinesia: potential for new therapies","volume":"2","author":"Bezard","year":"2001","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib7","doi-asserted-by":"crossref","first-page":"153","DOI":"10.1517\/13543784.2012.651457","article-title":"New pharmacological avenues for the treatment of l-DOPA-induced dyskinesias in Parkinson's disease: targeting glutamate and adenosine receptors","volume":"21","author":"Blandini","year":"2012","journal-title":"Expert Opin. Investig. Drugs"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib8","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1124\/jpet.108.140897","article-title":"Continuous and intermittent nicotine treatment reduces l-3,4-dihydroxyphenylalanine (l-DOPA)-induced dyskinesias in a rat model of Parkinson's disease","volume":"327","author":"Bordia","year":"2008","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib9","doi-asserted-by":"crossref","first-page":"929","DOI":"10.1124\/jpet.109.162396","article-title":"Nicotinic receptor-mediated reduction in l-dopa-induced dyskinesias may occur via desensitization","volume":"333","author":"Bordia","year":"2010","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib10","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/B978-0-12-381328-2.00005-5","article-title":"New approaches to therapy","volume":"98","author":"Brotchie","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib11","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1124\/jpet.108.145292","article-title":"Desensitization of nicotinic acetylcholine receptors as a strategy for drug development","volume":"328","author":"Buccafusco","year":"2009","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib12","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1016\/j.neuroscience.2011.07.070","article-title":"Contribution of pre-synaptic mechanisms to l-dopa-induced dyskinesia","volume":"198","author":"Carta","year":"2011","journal-title":"Neuroscience"},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2013.03.038_bib13","doi-asserted-by":"crossref","first-page":"S154","DOI":"10.1016\/j.parkreldis.2008.04.021","article-title":"Involvement of the serotonin system in l-dopa-induced dyskinesias","volume":"14","author":"Carta","year":"2008","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib14","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1016\/S0079-6123(08)00922-9","article-title":"Serotonin-dopamine interaction in the induction and maintenance of l-dopa-induced dyskinesias","volume":"172","author":"Carta","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib15","doi-asserted-by":"crossref","first-page":"1718","DOI":"10.1111\/j.1471-4159.2006.03696.x","article-title":"Role of striatal l-dopa in the production of dyskinesia in 6-hydroxydopamine lesioned rats","volume":"96","author":"Carta","year":"2006","journal-title":"J.\u00a0Neurochem."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib16","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1016\/j.conb.2008.01.004","article-title":"Advances in understanding l-dopa-induced dyskinesia","volume":"17","author":"Cenci","year":"2007","journal-title":"Curr. Opin. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib17","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1016\/S0079-6123(10)83011-0","article-title":"Maladaptive striatal plasticity in l-dopa-induced dyskinesia","volume":"183C","author":"Cenci","year":"2010","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib18","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1046\/j.1460-9568.1998.00285.x","article-title":"l-dopa-induced dyskinesia in the rat is associated with striatal overexpression of prodynorphin- and glutamic acid decarboxylase mRNA","volume":"10","author":"Cenci","year":"1998","journal-title":"Eur. J. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib19","first-page":"1","article-title":"Ratings of l-dopa-induced dyskinesia in the unilateral 6-OHDA lesion model of Parkinson's disease in rats and mice","author":"Cenci","year":"2007","journal-title":"Curr. Protoc. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib20","doi-asserted-by":"crossref","first-page":"670","DOI":"10.2174\/187152711797247885","article-title":"Current options and future possibilities for the treatment of dyskinesia and motor fluctuations in Parkinson's disease","volume":"10","author":"Cenci","year":"2011","journal-title":"CNS Neurol. Disord. Drug Targets"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib21","doi-asserted-by":"crossref","first-page":"574","DOI":"10.1038\/nrn877","article-title":"Animal models of neurological deficits: how relevant is the rat?","volume":"3","author":"Cenci","year":"2002","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib22","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1016\/S0028-3908(98)00221-4","article-title":"Characterisation of the binding of [3H]methyllycaconitine: a new radioligand for labelling alpha 7-type neuronal nicotinic acetylcholine receptors","volume":"38","author":"Davies","year":"1999","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib23","doi-asserted-by":"crossref","first-page":"610","DOI":"10.1002\/syn.20630","article-title":"The role of the dorsal raphe nucleus in the development, expression, and treatment of l-dopa-induced dyskinesia in hemiparkinsonian rats","volume":"63","author":"Eskow","year":"2009","journal-title":"Synapse"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib24","doi-asserted-by":"crossref","first-page":"306","DOI":"10.1016\/j.pbb.2007.05.002","article-title":"The partial 5-HT(1A) agonist buspirone reduces the expression and development of l-DOPA-induced dyskinesia in rats and improves l-DOPA efficacy","volume":"87","author":"Eskow","year":"2007","journal-title":"Pharmacol. Biochem. Behav."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib25","doi-asserted-by":"crossref","first-page":"95","DOI":"10.1016\/B978-0-12-381328-2.00004-3","article-title":"Molecular mechanisms of l-DOPA-induced dyskinesia","volume":"98","author":"Fisone","year":"2011","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib26","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1016\/S0079-6123(08)00923-0","article-title":"Parkinson's disease\u2013opportunities for novel therapeutics to reduce the problems of levodopa therapy","volume":"172","author":"Fox","year":"2008","journal-title":"Prog. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib27","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1146\/annurev-neuro-061010-113641","article-title":"Modulation of striatal projection systems by dopamine","volume":"34","author":"Gerfen","year":"2011","journal-title":"Annu. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib28","doi-asserted-by":"crossref","first-page":"703","DOI":"10.1016\/j.bcp.2009.05.024","article-title":"Structural and functional diversity of native brain neuronal nicotinic receptors","volume":"78","author":"Gotti","year":"2009","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib29","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1007\/s12031-009-9263-y","article-title":"Mouse striatal dopamine nerve terminals express alpha4alpha5beta2 and two stoichiometric forms of alpha4beta2*-nicotinic acetylcholine receptors","volume":"40","author":"Grady","year":"2010","journal-title":"J.\u00a0Mol. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib30","doi-asserted-by":"crossref","first-page":"2102","DOI":"10.1523\/JNEUROSCI.5059-04.2005","article-title":"Involvement of sensorimotor, limbic, and associative basal ganglia domains in L-3,4-dihydroxyphenylalanine-induced dyskinesia","volume":"25","author":"Guigoni","year":"2005","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib31","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.brainresbull.2008.09.013","article-title":"The cortico-basal ganglia integrative network: the role of the thalamus","volume":"78","author":"Haber","year":"2009","journal-title":"Brain Res. Bull."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib32","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1124\/mol.110.066381","article-title":"alpha4beta2 nicotinic receptors partially mediate anti-inflammatory effects through Janus kinase 2-signal transducer and activator of transcription 3 but not calcium or cAMP signaling","volume":"79","author":"Hosur","year":"2011","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib33","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1124\/jpet.111.182949","article-title":"Nicotine reduces l-dopa-induced dyskinesias by acting at {beta}2 nicotinic receptors","volume":"338","author":"Huang","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib34","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.neuropharm.2010.12.032","article-title":"Nicotinic receptor agonists decrease l-dopa-induced dyskinesias most effectively in moderately lesioned parkinsonian rats","volume":"60","author":"Huang","year":"2011","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib35","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1124\/jpet.111.184093","article-title":"Anatomically selective serotonergic type 1A and serotonergic type 2A therapies for Parkinson's disease: an approach to reducing dyskinesia without exacerbating parkinsonism?","volume":"339","author":"Huot","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib36","doi-asserted-by":"crossref","first-page":"441","DOI":"10.1124\/jpet.112.198085","article-title":"Chronic sazetidine-A at behaviorally active doses does not increase nicotinic cholinergic receptors in rodent brain","volume":"343","author":"Hussmann","year":"2012","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib37","doi-asserted-by":"crossref","first-page":"1661","DOI":"10.1007\/s00702-011-0698-2","article-title":"Mechanisms underlying the onset and expression of levodopa-induced dyskinesia and their pharmacological manipulation","volume":"118","author":"Iravani","year":"2011","journal-title":"J.\u00a0Neural Transm."},{"issue":"Suppl. 1","key":"10.1016\/j.neuropharm.2013.03.038_bib38","doi-asserted-by":"crossref","first-page":"S123","DOI":"10.1016\/S1353-8020(11)70038-4","article-title":"Striatal plasticity in Parkinson's disease and l-DOPA induced dyskinesia","volume":"18","author":"Iravani","year":"2012","journal-title":"Parkinsonism Relat. Disord."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib39","doi-asserted-by":"crossref","first-page":"665","DOI":"10.1038\/nrn2471","article-title":"Molecular mechanisms of l-dopa-induced dyskinesia","volume":"9","author":"Jenner","year":"2008","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib40","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1124\/mol.58.2.312","article-title":"alpha-Bungarotoxin-sensitive nicotinic receptors indirectly modulate [(3)H]dopamine release in rat striatal slices via glutamate release","volume":"58","author":"Kaiser","year":"2000","journal-title":"Mol. Pharmacol."},{"issue":"Suppl. 2","key":"10.1016\/j.neuropharm.2013.03.038_bib41","doi-asserted-by":"crossref","first-page":"95","DOI":"10.3233\/JAD-2011-110173","article-title":"Stimulating nicotinic receptors trigger multiple pathways attenuating cytotoxicity in models of Alzheimer's and Parkinson's diseases","volume":"24","author":"Kawamata","year":"2011","journal-title":"J.\u00a0Alzheimers Dis."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib42","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1124\/jpet.102.039347","article-title":"Declines in different beta2* nicotinic receptor populations in monkey striatum after nigrostriatal damage","volume":"303","author":"Kulak","year":"2002","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib43","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1016\/j.bcp.2011.06.022","article-title":"Progress and challenges in the study of alpha6-containing nicotinic acetylcholine receptors","volume":"82","author":"Letchworth","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib44","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1016\/S0026-895X(25)10280-0","article-title":"The binding of L-[3H]nicotine to a single class of high affinity sites in rat brain membranes","volume":"29","author":"Lippiello","year":"1986","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib45","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1124\/jpet.111.185306","article-title":"Varenicline is a potent agonist of the human 5-hydroxytryptamine3 receptor","volume":"339","author":"Lummis","year":"2011","journal-title":"J.\u00a0Pharmacol. Exp. Ther."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib46","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1007\/s12311-011-0331-9","article-title":"Consensus paper: roles of the cerebellum in motor control\u2013the diversity of ideas on cerebellar involvement in movement","volume":"11","author":"Manto","year":"2012","journal-title":"Cerebellum"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib47","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1007\/s00213-010-2028-z","article-title":"Desensitization of delta-opioid receptors in nucleus accumbens during nicotine withdrawal","volume":"213","author":"McCarthy","year":"2011","journal-title":"Psychopharmacology (Berl)"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib48","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1038\/nrd3430","article-title":"Priorities in Parkinson's disease research","volume":"10","author":"Meissner","year":"2011","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib49","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.neuropharm.2008.07.041","article-title":"Diversity of vertebrate nicotinic acetylcholine receptors","volume":"56","author":"Millar","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib50","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1016\/j.neuropharm.2009.12.024","article-title":"Effect of the metabotropic glutamate receptor type 5 antagonists MPEP and MTEP in parkinsonian monkeys","volume":"58","author":"Morin","year":"2010","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib51","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1007\/s00702-006-0561-z","article-title":"Nicotinic receptor agonists as neuroprotective\/neurotrophic drugs. Progress in molecular mechanisms","volume":"114","author":"Mudo","year":"2007","journal-title":"J.\u00a0Neural Transm."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib52","doi-asserted-by":"crossref","first-page":"S2","DOI":"10.1016\/S1471-1931(00)00031-8","article-title":"Levodopa motor complications in Parkinson's disease","volume":"23","author":"Obeso","year":"2000","journal-title":"Trends Neurosci."},{"issue":"Suppl. 3","key":"10.1016\/j.neuropharm.2013.03.038_bib53","doi-asserted-by":"crossref","first-page":"S548","DOI":"10.1002\/mds.22062","article-title":"Functional organization of the basal ganglia: therapeutic implications for Parkinson's disease","volume":"23","author":"Obeso","year":"2008","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib54","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1038\/nm.2165","article-title":"Missing pieces in the Parkinson's disease puzzle","volume":"16","author":"Obeso","year":"2010","journal-title":"Nat. Med."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib55","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1016\/j.bbr.2011.09.044","article-title":"Parallel contributions of cerebellar, striatal and M1 mechanisms to motor sequence learning","volume":"226","author":"Penhune","year":"2012","journal-title":"Behav. Brain Res."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib56","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1016\/j.pneurobio.2007.12.005","article-title":"It is not \u201ceither\/or\u201d: activation and desensitization of nicotinic acetylcholine receptors both contribute to behaviors related to nicotine addiction and mood","volume":"84","author":"Picciotto","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib57","doi-asserted-by":"crossref","first-page":"492","DOI":"10.2741\/2695","article-title":"Neuroprotection via nAChRs: the role of nAChRs in neurodegenerative disorders such as Alzheimer's and Parkinson's disease","volume":"13","author":"Picciotto","year":"2008","journal-title":"Front. Biosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib58","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1002\/ana.21203","article-title":"Nicotine reduces levodopa-induced dyskinesias in lesioned monkeys","volume":"62","author":"Quik","year":"2007","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib59","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.nbd.2012.09.006","article-title":"Nicotine-mediated improvement in l-dopa-induced dyskinesias in MPTP-lesioned monkeys is dependent on dopamine nerve terminal function","volume":"50","author":"Quik","year":"2013","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib60","doi-asserted-by":"crossref","first-page":"450","DOI":"10.1016\/j.neuropharm.2012.04.029","article-title":"Role for alpha6 nicotinic receptors in l-dopa-induced dyskinesias in parkinsonian mice","volume":"63","author":"Quik","year":"2012","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib61","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1016\/j.bcp.2011.06.001","article-title":"Role of alpha6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders","volume":"82","author":"Quik","year":"2011","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib62","doi-asserted-by":"crossref","first-page":"5494","DOI":"10.1523\/JNEUROSCI.21-15-05494.2001","article-title":"Vulnerability of 125I-alpha-conotoxin MII binding sites to nigrostriatal damage in monkey","volume":"21","author":"Quik","year":"2001","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib63","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1124\/mol.63.5.1169","article-title":"Differential declines in striatal nicotinic receptor subtype function after nigrostriatal damage in mice","volume":"63","author":"Quik","year":"2003","journal-title":"Mol. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib64","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1124\/pr.110.003269","article-title":"{alpha}6{beta}2* and {alpha}4{beta}2* nicotinic acetylcholine receptors as drug targets for Parkinson's disease","volume":"63","author":"Quik","year":"2011","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib65","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1002\/mds.23714","article-title":"Milestones in Parkinson's disease therapeutics","volume":"26","author":"Rascol","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib66","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1016\/j.neuropharm.2009.10.007","article-title":"Effect of the alpha(4)beta(2)( *) nicotinic acetylcholine receptor partial agonist varenicline on dopamine release in beta2 knock-out mice with selective re-expression of the beta2 subunit in the ventral tegmental area","volume":"58","author":"Reperant","year":"2009","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib67","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1016\/j.ejphar.2012.02.031","article-title":"Effects of sazetidine-A, a selective alpha4beta2* nicotinic receptor desensitizing agent, on body temperature regulation in mice and rats","volume":"682","author":"Rezvani","year":"2012","journal-title":"Eur. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib68","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/j.1476-5381.2010.00682.x","article-title":"Pre-clinical properties of the alpha4beta2 nicotinic acetylcholine receptor partial agonists varenicline, cytisine and dianicline translate to clinical efficacy for nicotine dependence","volume":"160","author":"Rollema","year":"2010","journal-title":"Br. J. Pharmacol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib69","doi-asserted-by":"crossref","first-page":"352","DOI":"10.1016\/j.nbd.2010.05.001","article-title":"A\u00a0mGluR5 antagonist under clinical development improves l-dopa-induced dyskinesia in parkinsonian rats and monkeys","volume":"39","author":"Rylander","year":"2010","journal-title":"Neurobiol. Dis."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib70","doi-asserted-by":"crossref","first-page":"777","DOI":"10.1016\/S0028-3908(00)00005-8","article-title":"CNS plasticity and assessment of forelimb sensorimotor outcome in unilateral rat models of stroke, cortical ablation, parkinsonism and spinal cord injury","volume":"39","author":"Schallert","year":"2000","journal-title":"Neuropharmacology"},{"key":"10.1016\/j.neuropharm.2013.03.038_bib71","doi-asserted-by":"crossref","first-page":"1049","DOI":"10.1002\/mds.23732","article-title":"Etiology and pathogenesis of Parkinson's disease","volume":"26","author":"Schapira","year":"2011","journal-title":"Mov. Disord."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib72","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.pneurobio.2011.10.005","article-title":"Glutamatergic mechanisms in the dyskinesias induced by pharmacological dopamine replacement and deep brain stimulation for the treatment of Parkinson's disease","volume":"96","author":"Sgambato-Faure","year":"2012","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib73","doi-asserted-by":"crossref","first-page":"332","DOI":"10.1248\/bpb.32.332","article-title":"Nicotinic receptor-mediated neuroprotection in neurodegenerative disease models","volume":"32","author":"Shimohama","year":"2009","journal-title":"Biol. Pharm. Bull."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib74","doi-asserted-by":"crossref","first-page":"6790","DOI":"10.1523\/JNEUROSCI.22-15-06790.2002","article-title":"Forced nonuse in unilateral parkinsonian rats exacerbates injury","volume":"22","author":"Tillerson","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib75","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.pneurobio.2008.03.003","article-title":"Neurochemical pathways involved in the protective effects of nicotine and ethanol in preventing the development of Parkinson's disease: potential targets for the development of new therapeutic agents","volume":"85","author":"Ward","year":"2008","journal-title":"Prog. Neurobiol."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib76","doi-asserted-by":"crossref","first-page":"290","DOI":"10.1016\/0166-2236(90)90112-N","article-title":"Compensations after lesions of central dopaminergic neurons: some clinical and basic implications","volume":"13","author":"Zigmond","year":"1990","journal-title":"Trends Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib77","doi-asserted-by":"crossref","first-page":"8785","DOI":"10.1523\/JNEUROSCI.22-20-08785.2002","article-title":"Identification of the nicotinic receptor subtypes expressed on dopaminergic terminals in the rat striatum","volume":"22","author":"Zoli","year":"2002","journal-title":"J.\u00a0Neurosci."},{"key":"10.1016\/j.neuropharm.2013.03.038_bib78","doi-asserted-by":"crossref","first-page":"1838","DOI":"10.1124\/mol.108.045104","article-title":"Sazetidine-A is a potent and selective agonist at native and recombinant alpha 4 beta 2 nicotinic acetylcholine receptors","volume":"73","author":"Zwart","year":"2008","journal-title":"Mol. Pharmacol."}],"container-title":["Neuropharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813001342?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0028390813001342?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,4,30]],"date-time":"2025-04-30T05:06:01Z","timestamp":1745989561000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0028390813001342"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,8]]},"references-count":78,"alternative-id":["S0028390813001342"],"URL":"https:\/\/doi.org\/10.1016\/j.neuropharm.2013.03.038","relation":{},"ISSN":["0028-3908"],"issn-type":[{"value":"0028-3908","type":"print"}],"subject":[],"published":{"date-parts":[[2013,8]]}}}